<p>CenterBook Partners LP 在最近向美國證券交易委員會提交的文件中表示，在第三季度將其在 Humacyte, Inc. (NASDAQ:HUMA - 免費報告) 的持股比例削減了 91.7%。該機構投資者在此期間出售了 3,146,628 股後，持有該公司 283,627 股股票。CenterBook Partners LP 在最近的報告期末持有的 Humacyte 股票約佔 0.18%，價值 494,000 美元。</p>
<p>其他一些機構投資者和對沖基金最近也買賣了 HUMA 的股票。CWM LLC 在第二季度將其在 Humacyte 的持股比例提高了 29,921.4%。CWM LLC 現在持有 43,531 股該公司的股票，價值 91,000 美元，此前在此期間又購買了 43,386 股。Savant Capital LLC 在第二季度獲得了 Humacyte 的新頭寸，價值 122,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度購買了 Humacyte 的新頭寸，價值約 30,000 美元。SBI Securities Co. Ltd. 在第二季度將其在 Humacyte 的持股比例提高了 6,305.4%。SBI Securities Co. Ltd. 現在持有 68,218 股該公司的股票，價值 143,000 美元，此前在上個季度又收購了 67,153 股。最後，Letko Brosseau &amp; Associates Inc. 在第二季度將其在 Humacyte 的持股比例提高了 85.3%。Letko Brosseau &amp; Associates Inc. 現在持有 45,950 股該公司的股票，價值 96,000 美元，此前在上個季度又收購了 21,150 股。對沖基金和其他機構投資者持有該公司 44.71% 的股票。</p>
<h2>Humacyte 股票下跌 1.7%</h2>
<p>NASDAQ:HUMA 的股票在週五開盤時為 1.13 美元。該公司的 50 日移動平均線為 1.06 美元，200 日移動平均線為 1.39 美元。該公司的債務與股本比率為 2.97，速動比率為 0.90，流動比率為 1.62。Humacyte, Inc. 的 1 年最低價為 0.88 美元，1 年最高價為 3.94 美元。該股票的市值為 2.1162 億美元，市盈率為 -4.91，貝塔值為 1.93。</p>
<h2>分析師評級調整</h2>
<p>HUMA 曾受到多份分析師報告的關注。D. Boral Capital 在週四的研究報告中重申了對 Humacyte 的 &#34;買入&#34; 評級，並設定了 25.00 美元的目標價。Benchmark 在 1 月 21 日的研究報告中將 Humacyte 的目標價從 11.00 美元下調至 10.00 美元，並對該公司設定了 &#34;買入&#34; 評級。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Humacyte 的 &#34;賣出 (d-)&#34; 評級。Wall Street Zen 在 12 月 21 日的報告中將 Humacyte 的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。最後，BTIG Research 在 2 月 9 日的研究報告中重申了對 Humacyte 的 &#34;買入&#34; 評級，並設定了 6.00 美元的目標價。七位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 8.14 美元。</p>
<p><strong>閲讀我們關於 HUMA 的最新報告</strong></p>
<h2>Humacyte 公司簡介</h2>
<p>(免費報告)</p>
<p>Humacyte, Inc 是一家臨牀階段的生物技術公司，專注於開發和製造現成的再生人類無細胞血管 (HAVs)，旨在滿足關鍵的血管通路需求。該公司的專有血管由人類供體細胞工程化而成，然後去細胞化，以創建一種能夠與患者自身組織整合的生物相容性支架。Humacyte 的主要業務活動包括 HAVs 的工藝開發、大規模生產和臨牀評估，適用於終末期腎病、外周動脈疾病和其他血管修復應用。</p>
<p>該公司的主要產品候選者 HAV 已通過多項臨牀試驗，針對血液透析患者的動靜脈通路，顯示出耐用性、降低感染率和與重複穿刺的兼容性。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Humacyte</li>
<li>~$1.5T SpaceX IPO：首次公開募股機會</li>
<li>黃金 $5,000:2026 年黃金與白銀峯會將於 3 月 4 日直播</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
<li>Elon Musk：這可能將 $100 變成 $100,000</li>
</ul>
<p><strong>想看看其他對沖基金持有的 HUMA 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Humacyte, Inc. (NASDAQ:HUMA - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Humacyte 嗎？</h2>
<p>在考慮 Humacyte 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Humacyte 並不在名單上。</p>
<p>雖然 Humacyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

紐交所高增長板生物技術指數 ETF - First Trust

IBBQ

動態生物技術與基因組 ETF - Invesco

HUMA

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

<p>CenterBook Partners LP 在第三季度大幅減少了對 Humacyte, Inc. (NASDAQ:HUMA) 的持股，減少幅度達到 91.7%，目前持有 283,627 股，之前出售了 3,146,628 股。其他機構投資者也調整了他們的持倉。Humacyte 的股票目前下跌 1.7%，交易價格為 1.13 美元，市值為 2.1162 億美元。分析師的評級意見不一，普遍評級為 “適度買入”，目標價格為 8.14 美元。Humacyte 專注於開發用於血管通路需求的再生人類無細胞血管</p>

<p>CenterBook Partners LP cut its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 91.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 283,627 shares of the company's stock after selling 3,146,628 shares during the period. CenterBook Partners LP owned approximately 0.18% of Humacyte worth $494,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>CenterBook Partners LP 在最近向美國證券交易委員會提交的文件中表示，在第三季度將其在 Humacyte, Inc. (NASDAQ:HUMA - 免費報告) 的持股比例削減了 91.7%。該機構投資者在此期間出售了 3,146,628 股後，持有該公司 283,627 股股票。CenterBook Partners LP 在最近的報告期末持有的 Humacyte 股票約佔 0.18%，價值 494,000 美元。</p>
</div><p>A number of other institutional investors and hedge funds have also recently bought and sold shares of HUMA. CWM LLC boosted its stake in shares of Humacyte by 29,921.4% in the second quarter. CWM LLC now owns 43,531 shares of the company's stock valued at $91,000 after purchasing an additional 43,386 shares during the period. Savant Capital LLC acquired a new position in Humacyte in the 2nd quarter worth $122,000. Vanguard Personalized Indexing Management LLC purchased a new position in Humacyte in the 2nd quarter valued at about $30,000. SBI Securities Co. Ltd. grew its stake in shares of Humacyte by 6,305.4% during the second quarter. SBI Securities Co. Ltd. now owns 68,218 shares of the company's stock valued at $143,000 after acquiring an additional 67,153 shares in the last quarter. Finally, Letko Brosseau &amp; Associates Inc. increased its position in shares of Humacyte by 85.3% during the second quarter. Letko Brosseau &amp; Associates Inc. now owns 45,950 shares of the company's stock worth $96,000 after acquiring an additional 21,150 shares during the last quarter. Hedge funds and other institutional investors own 44.71% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也買賣了 HUMA 的股票。CWM LLC 在第二季度將其在 Humacyte 的持股比例提高了 29,921.4%。CWM LLC 現在持有 43,531 股該公司的股票，價值 91,000 美元，此前在此期間又購買了 43,386 股。Savant Capital LLC 在第二季度獲得了 Humacyte 的新頭寸，價值 122,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度購買了 Humacyte 的新頭寸，價值約 30,000 美元。SBI Securities Co. Ltd. 在第二季度將其在 Humacyte 的持股比例提高了 6,305.4%。SBI Securities Co. Ltd. 現在持有 68,218 股該公司的股票，價值 143,000 美元，此前在上個季度又收購了 67,153 股。最後，Letko Brosseau &amp; Associates Inc. 在第二季度將其在 Humacyte 的持股比例提高了 85.3%。Letko Brosseau &amp; Associates Inc. 現在持有 45,950 股該公司的股票，價值 96,000 美元，此前在上個季度又收購了 21,150 股。對沖基金和其他機構投資者持有該公司 44.71% 的股票。</p>
</div><h2>Humacyte Stock Down 1.7%</h2>
<div class="lb-trans"><h2>Humacyte 股票下跌 1.7%</h2>
</div><p>Shares of NASDAQ:HUMA opened at $1.13 on Friday. The company's fifty day moving average is $1.06 and its two-hundred day moving average is $1.39. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte, Inc. has a 1-year low of $0.88 and a 1-year high of $3.94. The stock has a market capitalization of $211.62 million, a price-to-earnings ratio of -4.91 and a beta of 1.93.</p>
<div class="lb-trans"><p>NASDAQ:HUMA 的股票在週五開盤時為 1.13 美元。該公司的 50 日移動平均線為 1.06 美元，200 日移動平均線為 1.39 美元。該公司的債務與股本比率為 2.97，速動比率為 0.90，流動比率為 1.62。Humacyte, Inc. 的 1 年最低價為 0.88 美元，1 年最高價為 3.94 美元。該股票的市值為 2.1162 億美元，市盈率為 -4.91，貝塔值為 1.93。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>HUMA has been the subject of a number of analyst reports. D. Boral Capital restated a &#34;buy&#34; rating and set a $25.00 price objective on shares of Humacyte in a research note on Thursday. Benchmark reduced their target price on Humacyte from $11.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, January 21st. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Humacyte in a research report on Monday, December 29th. Wall Street Zen cut shares of Humacyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, December 21st. Finally, BTIG Research reiterated a &#34;buy&#34; rating and set a $6.00 price objective on shares of Humacyte in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.14.</p>
<div class="lb-trans"><p>HUMA 曾受到多份分析師報告的關注。D. Boral Capital 在週四的研究報告中重申了對 Humacyte 的 &#34;買入&#34; 評級，並設定了 25.00 美元的目標價。Benchmark 在 1 月 21 日的研究報告中將 Humacyte 的目標價從 11.00 美元下調至 10.00 美元，並對該公司設定了 &#34;買入&#34; 評級。Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Humacyte 的 &#34;賣出 (d-)&#34; 評級。Wall Street Zen 在 12 月 21 日的報告中將 Humacyte 的評級從 &#34;持有&#34; 下調至 &#34;賣出&#34;。最後，BTIG Research 在 2 月 9 日的研究報告中重申了對 Humacyte 的 &#34;買入&#34; 評級，並設定了 6.00 美元的目標價。七位投資分析師對該股票給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 &#34;適度買入&#34;，共識目標價為 8.14 美元。</p>
</div><p><strong>Read Our Latest Report on HUMA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 HUMA 的最新報告</strong></p>
</div><h2>Humacyte Profile</h2>
<div class="lb-trans"><h2>Humacyte 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.</p>
<div class="lb-trans"><p>Humacyte, Inc 是一家臨牀階段的生物技術公司，專注於開發和製造現成的再生人類無細胞血管 (HAVs)，旨在滿足關鍵的血管通路需求。該公司的專有血管由人類供體細胞工程化而成，然後去細胞化，以創建一種能夠與患者自身組織整合的生物相容性支架。Humacyte 的主要業務活動包括 HAVs 的工藝開發、大規模生產和臨牀評估，適用於終末期腎病、外周動脈疾病和其他血管修復應用。</p>
</div><p>The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.</p>
<div class="lb-trans"><p>該公司的主要產品候選者 HAV 已通過多項臨牀試驗，針對血液透析患者的動靜脈通路，顯示出耐用性、降低感染率和與重複穿刺的兼容性。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Humacyte</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold $5,000: The 2026 Gold &amp; Silver Summit is LIVE March 4</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
<li>Elon Musk: This Could Turn $100 into $100,000</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Humacyte</li>
<li>~$1.5T SpaceX IPO：首次公開募股機會</li>
<li>黃金 $5,000:2026 年黃金與白銀峯會將於 3 月 4 日直播</li>
<li>家族信託如何幫助保護您的財富</li>
<li>這讓我感到憤怒</li>
<li>Elon Musk：這可能將 $100 變成 $100,000</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HUMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 HUMA 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Humacyte, Inc. (NASDAQ:HUMA - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFVNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=HUMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Humacyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Humacyte 嗎？</h2>
</div><p>Before you consider Humacyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Humacyte 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Humacyte 並不在名單上。</p>
</div><p>While Humacyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Humacyte 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP

Market Beat

Invesco Nasdaq Biotechnology ETF

Humacyte

CenterBook Partners LP 出售了 Humacyte, Inc. 的 $HUMA 股份